This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both medicines can increase your risk of angioedema.
What might happen:
You may develop angioedema, a potential life-threatening condition that causes swelling of the face, lips, tongue, and/or throat.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together. If you are switching from one medicine to the other, you should wait 36 hours between stopping one medicine and starting the other. If you experience swelling of the face, lips, tongue, and/or throat and/or have trouble breathing, seek emergency medical attention right away.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.FDA. CDER Application Number 207620Orig1s000 Entresto (sacubitril/valsartan) Clinical Pharmacology and Biopharmaceutics Review(s). available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000Clin PharmR.pdf August 14, 2015.
2.FDA. CDER Application Number 207620Orig1s000 Entresto (sacubitril/valsartan) Medical Review(s). available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000MedR .pdf August 14, 2015.
3.Entresto (sacubitril-valsartan) US prescribing information. Novartis Pharmaceuticals Corporation July 7, 2015.